Stock listing

TASE:CANF Can-Fite BioPharma Ltd. מניה‎

Home listing (TASE) of Can-Fite BioPharma Ltd.

Follow Can-Fite BioPharma Ltd. into a list and get an email when it puts out news.

Share price · TASE:CANF

268.70 ILA (agorot) +13.70 (+5.4%)

Close on Nov 19, 2026

Past year -62.7% · daily closes, Jan 5, 2026 – Nov 19, 2026, adjusted for splits
Day range
268.70 – 268.70 ILA (agorot)Nov 19, 2026
Market cap
16.29M ILSAt the close on Nov 19, 2026 · price × 6.06M shares outstanding
Traded on an average day
66,496 ILSMedian day 8,571 shares · 1 day with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Can-Fite BioPharma Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:CANF · Home268.70 ILA (agorot)+13.70 (+5.4%)—268.70268.70268.70255.00Close on Nov 19, 2026
NYSE American:CANF$1.435 USD-0.034 (-2.3%)16,823$1.48$1.533$1.42$1.469Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:CANF · ILA (agorot), adjusted for splits

DayCloseChange%OpenHighLowVolume
268.70+13.70+5.4%268.70268.70268.700
255.00+5.30+2.1%258.50275.00250.0014,211
249.70-1.30-0.5%251.10265.00244.0039,825
251.00+0.90+0.4%258.90262.90250.0030,825
250.10-12.90-4.9%257.00275.00250.0036,891
263.00-16.70-6.0%270.70279.20257.308,779
279.70+9.80+3.6%271.60283.30263.002,983
269.90-10.10-3.6%280.00284.50261.0011,910
280.00+20.00+7.7%271.10280.00258.003,425
260.000.000.0%256.30285.00256.3013,474
260.00-2.00-0.8%268.90268.90250.1028,314
262.00-8.50-3.1%275.00285.00260.5011,213
270.50+7.20+2.7%263.30282.90260.0034,110
263.30+6.30+2.5%262.90264.10256.004,670
257.00-12.40-4.6%263.90266.00257.004,877
269.40+1.40+0.5%278.90281.40260.6010,900
268.00-36.60-12.0%293.00325.00257.30127,772
304.60-3.90-1.3%303.30304.60295.505,936
308.50+9.50+3.2%306.00308.50298.606,383
299.00-1.20-0.4%305.00309.40299.00426
300.20-5.40-1.8%310.00310.00300.202,000
305.60-1.40-0.5%313.50313.50299.0016,358
307.00-4.90-1.6%305.60314.80300.003,965
311.90+2.10+0.7%306.80319.60300.002,389
309.80+2.20+0.7%306.20309.80306.006,520
307.60-2.80-0.9%305.00323.90299.009,856
310.40-7.80-2.5%313.50319.50299.0013,753
318.20+8.20+2.6%311.00318.20311.00375
310.00-10.00-3.1%320.10325.00309.0016,081
320.00-21.00-6.2%338.20338.20320.0040,563
341.00+11.00+3.3%341.00341.00341.00293
330.00-0.80-0.2%330.80340.90330.003,940
330.80+1.40+0.4%330.00340.70330.002,276
329.40-11.40-3.3%340.80340.80325.008,363
340.80-0.50-0.1%341.30341.30330.102,015
341.30-5.30-1.5%345.50345.50336.002,076
346.60+11.80+3.5%334.80349.90333.001,775
334.80-6.60-1.9%339.30356.00332.009,886
341.40-10.10-2.9%349.90366.90335.0023,481
351.50+3.50+1.0%345.30360.00345.0010,709
348.00+5.80+1.7%348.90349.00340.3025,155
342.20-5.90-1.7%349.70359.40342.007,326
348.10+6.60+1.9%351.80360.00346.3018,422
341.50-1.50-0.4%340.80360.00340.404,421
343.00-9.00-2.6%364.90364.90343.0040,554
352.00-22.00-5.9%370.50380.00348.0055,071
374.00-2.40-0.6%355.00380.00348.0051,563
376.40+12.80+3.5%364.80383.80364.8027,035
363.60-40.20-10.0%390.00390.00362.0098,699
403.80-86.60-17.7%495.10699.00399.80228,292
490.40-24.50-4.8%507.00517.90490.0010,044
514.90+8.80+1.7%507.70529.00498.005,926
506.10-9.50-1.8%515.60529.00506.005,303
515.60-1.60-0.3%506.00535.00505.508,039
517.20+8.20+1.6%515.20538.90506.001,899
509.00-2.00-0.4%511.00547.90509.003,572
511.00-26.20-4.9%537.20548.90511.0013,744
537.20+6.50+1.2%537.20544.50537.20183
530.70-2.20-0.4%532.90544.90510.101,157
532.90+22.90+4.5%531.10540.40520.004,131

Splits

2 splits since 2013 · TASE:CANF · every price before a split is adjusted for it

DayRatioWhat
1-for-3000Consolidation
1-for-25Consolidation
Ticker
TASE:CANF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TASE
Currency
ILA

What changed lately

Latest news

All Can-Fite BioPharma Ltd. news

Can-Fite BioPharma Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 36 in all · newest Sep 8, 2026 · oldest 2025
Calls
1 call with a replay · 1 with a transcript · latest Nov 30, 2020
Decks
13 decks · latest November 2025

Where Can-Fite BioPharma Ltd. is listed

ListingExchangeCountryCurrency
TASE:CANF · Home listing · This pageTASEIsraelILA
NYSE American:CANFNYSE AmericanUnited StatesUSD
BOATS:CANFBOATSUnited StatesUSD

Valuation

EV/sales −5.3× against a median of 8.2×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
−7.17M ILS
P/E
Loss
EV/sales
−5.3×
EV/EBITDA
Negative EBITDA
Price/book
1.0×
Gross margin
100.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Can-Fite BioPharma Ltd. · TASE:CANFUS$4.86M−US$2.14Mn/a−5.3×n/a1.0×n/a0.0×n/a
Rakovina Therapeutics Inc · TSXV:RKVUS$5.10MUS$7.20Mn/an/an/an/an/an/a-0.43
StimCell Energetics Inc. · OTC:STMEUS$5.10MUS$5.09Mn/an/an/an/an/an/a0.99
Longeveron Inc. · NASDAQ:LGVNUS$5.05M−US$1.78Mn/a−1.5×n/a1.1×n/a0.1×1.55
Oncodesign Precision Medicine S.A. · EURONEXT:ALOPMUS$5.04MUS$8.61M0.8×30.0×0.9×1.2×n/a1.6×n/a
Patrys Limited · ASX:PABUS$4.96MUS$4.47Mn/a8.2×n/a10.2×−363.7%0.0×n/a
Invex Therapeutics Ltd. · ASX:IXCUS$4.86MUS$2.20Mn/an/an/a1.9×n/a0.0×n/a
Zenith Capital Corporation · OTC:ZHCLFUS$4.83Mn/an/an/an/an/an/an/a0.06
NFL Biosciences SA · EURONEXT:ALNFLUS$4.71MUS$5.36Mn/an/an/an/an/an/an/a
TheraCryf PLC · LSE:TCFUS$4.64MUS$2.63Mn/an/an/a1.3×n/a0.0×n/a
Pulmatrix, Inc. · NASDAQ:PULMUS$4.64MUS$3.24Mn/an/an/a3.5×n/a0.0×0.33
Median of the othersUS$4.91MUS$4.47M0.8×8.2×0.9×1.6×−363.7%0.0×0.33

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
6.00 ILA · Analysts' mean
EPS, year to Dec 2026
-3.02 · 1 analyst
Revenue, year to Dec 2026
404K · 1 analyst

Team and board

Officers

OfficerRole
Guy RegevChief Executive Officer
Motti FarbsteinCEO, CFO
Yossi BornsteinCEO
Sari FishmanVice President of Business Development
Pnina FishmanExecutive Chairperson, CSO

Board

DirectorRole
Pnina FishmanExecutive Chairperson, CSO
Abraham SartaniMember of the Board of Directors
Guy RegevChief Executive Officer
Yossi BornsteinCEO

Events

Calls

CallWhenStatus
Can-Fite BioPharma (TASE:CANF) Q3 2020 Earnings CallMon, Nov 30, 2020 · 9:15 AM ETReplay

Results days

QuarterResults
Q4 2023Mar 28, 2024 · Before open
Q3 2023Nov 30, 2023 · Before open
Q2 2023Aug 31, 2023 · Before open
Q3 2022Nov 25, 2022 · Before open
Q3 2021Nov 26, 2021 · Before open
Quarter to Jun 30, 2021Aug 26, 2021 · Before open
Quarter to Dec 31, 2020Mar 25, 2021 · Before open

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck29 slidesNovember 2025
Investor Presentation (February 2025)Investor deck23 slidesFeb 5, 2025
Investor Presentation (September 2023)Investor deck22 slidesSep 7, 2023
Investor Presentation (March 2020)Investor deck20 slidesMar 9, 2020
Investor Presentation (September 2019)Investor deck19 slidesSep 6, 2019
Investor Presentation (February 2019)Investor deck19 slidesFeb 1, 2019
Investor Presentation (September 2017)Investor deck22 slidesSep 8, 2017
Investor Presentation (January 2017)Investor deck20 slidesJan 6, 2017
Investor Presentation (January 2016)Investor deck21 slidesJan 11, 2016
Investor Presentation (September 2015)Investor deck22 slidesSep 9, 2015
All 13 decks
DeckKindSlidesDate
Investor Presentation (May 2015)Investor deck23 slidesMay 29, 2015
Investor Presentation (July 2014)Investor deck20 slidesJul 8, 2014
Investor Presentation (October 2013)Investor deck20 slidesOct 31, 2013

Open Decks

Financings

RaiseDate
Warrant exercise of american Depositary Shares upon exercise of warrants
Announced: about US$4M · US$5 a share · Warrants at US$5 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes
Mar 4, 2026
Public offering of american Depositary Shares (or pre-funded warrants) with short-term warrants
Announced: about US$5M · US$0.6 a share · Warrants at US$0.6 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes
Jul 28, 2025
Registered direct offering of american Depositary Shares
Announced: US$3M · US$1.2 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes
Apr 14, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue405.0K674.0K743.0K810.0K853.0K763.0K2.03M3.82M789.0K169.5K
Cost of revenue26.0K000
Gross profit412.4K674.0K743.0K810.0K853.0K763.0K2.03M3.82M844.7K169.5K
Research and development6.69M5.76M5.98M7.76M9.85M12.0M11.0M6.08M5.11M6.12M
Selling, general and administrative3.66M3.05M2.96M263.0K466.0K317.0K3.06M3.16M2.92M2.70M
Operating income-9.95M-8.13M-8.20M-10.1M-12.8M-14.1M-12.0M-5.41M-7.18M-8.63M
Depreciation and amortization24.0K7.00K15.0K14.0K14.0K12.0K14.0K14.0K19.0K18.5K
EBITDA-9.93M-8.12M-8.18M-10.1M-12.8M-14.1M-12.0M-5.40M-7.17M-8.62M
Interest expense284.0K291.0K506.0K-222.0K18.0K363.0K427.0K1.20M1.10M27.3K
Income before tax-9.83M-7.88M-7.63M-10.2M-12.6M-14.4M-12.6M-6.57M-4.81M-6.99M
Income tax360.0K-20.0K427.0K4.00K29.0K29.1K
Net income-9.83M-7.88M-7.63M-10.2M-12.6M-14.4M-12.6M-6.57M-4.84M-8.39M
Earnings per share, basic-5.97-10.86-17.92-0.01-0.03-0.04-0.14-0.17-0.14-0.21
Earnings per share, diluted-5.97-10.86-17.92-0.01-0.03-0.04-0.14-0.17-0.14

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.53M4.83M4.28M2.98M4.39M8.27M2.70M3.62M3.50M8.12M
Short-term investments1.00K5.00K19.0K8.00K237.0K75.0K64.0K273.0K
Receivables74.0K47.0K48.0K18.0K637.0K41.0K66.0K21.8K
Inventory-39.0K-48.0K-715.0K-3.97M-3.30M
Current assets9.44M8.98M9.91M9.16M20.1M9.40M7.14M7.90M6.87M10.1M
Property, plant and equipment5.00K27.0K29.0K42.0K47.0K50.0K36.0K47.0K28.0K40.0K
Total assets9.51M9.12M9.99M9.28M20.3M9.52M8.17M7.95M7.83M10.2M
Accounts payable1.16M618.0K427.0K896.0K954.0K561.0K2.16M1.07M427.0K1.25M
Current liabilities2.73M2.05M2.02M2.50M2.73M1.27M3.27M3.12M1.80M2.50M
Total debt71.0K104.0K40.0K62.0K124.0K67.0K75.0K
Total liabilities3.92M3.68M3.75M4.81M5.87M3.45M5.73M4.94M4.78M6.29M
Shareholders' equity5.59M5.44M6.24M4.47M14.4M6.07M2.44M3.02M2.98M3.91M
Shares outstanding2.62M994.4K1.36B815.7M815.7M463.8M120.7M40.4M463.8M40.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.95M-7.64M-8.44M-10.8M-9.86M-12.1M-11.1M-4.16M-8.97M-8.93M
Capital spending-2.00K-5.00K-2.00K-9.00K-11.0K-26.0K-3.00K-33.0K-7.00K-10.4K
Free cash flow-8.95M-7.64M-8.44M-10.8M-9.87M-12.1M-11.1M-4.19M-8.98M-8.94M
Cash from investing-2.00K1.50M498.0K9.50M-14.5M-26.0K-3.00K-33.0K-29.0K-10.4K
Cash from financing9.64M6.71M9.14M6.53M20.5M17.7M10.2M4.39M4.47M0
Dividends paid-2.59M-715.0K
Share buybacks17.0M17.0M
Change in cash703.0K547.0K1.30M-1.41M-3.88M5.57M-918.0K110.0K-4.61M-9.05M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerNov 9, 2026Current reportSEC
6-K · Report of a foreign issuerNov 2, 2026Current reportSEC
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveOct 13, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 13, 2026Other filingsSEC
424B3 · ProspectusOct 9, 2026Offer documentSEC
F-3 · Registration statementSep 28, 2026Offer documentSEC
F-3/A · Registration statement, amendedSep 25, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveSep 14, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 14, 2026Other filingsSEC
DSep 10, 2026Other filingsSEC
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
POS AM · Amendment to an effective registrationSep 8, 2026Offer documentSEC
POS AM · Amendment to an effective registrationSep 8, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 8, 2026Current reportSEC
6-K · Report of a foreign issuerSep 3, 2026Current reportSEC
6-K · Report of a foreign issuerSep 2, 2026Current reportSEC
6-K · Report of a foreign issuerSep 2, 2026Current reportSEC
F-3 · Registration statementAug 28, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 17, 2026Current reportSEC
6-K · Report of a foreign issuerAug 12, 2026Current reportSEC
6-K · Report of a foreign issuerAug 3, 2026Current reportSEC
6-K · Report of a foreign issuerJul 20, 2026Current reportSEC
6-K · Report of a foreign issuerJul 14, 2026Current reportSEC
6-K · Report of a foreign issuerJul 6, 2026Current reportSEC
6-K · Report of a foreign issuerJul 1, 2026Current reportSEC
6-K · Report of a foreign issuerJun 26, 2026Current reportSEC
6-K · Report of a foreign issuerJun 22, 2026Current reportSEC
6-K · Report of a foreign issuerJun 17, 2026Current reportSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
4 · Change in ownershipJun 8, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 4, 2026Current reportSEC
6-K · Report of a foreign issuerJun 2, 2026Current reportSEC
6-K · Report of a foreign issuerMay 28, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 13, 2026Current reportSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
3 · Initial statement of ownershipApr 23, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 6, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
424B3 · ProspectusApr 3, 2026Offer documentSEC
CORRESP · Letter to the SECApr 1, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 31, 2026Other filingsSEC
F-3 · Registration statementMar 30, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMar 30, 2026Offer documentSEC
POS AM · Amendment to an effective registrationMar 30, 2026Offer documentSEC
6-K · Report of a foreign issuerMar 30, 2026Current reportSEC
20-F · Annual reportMar 26, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 26, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 17, 2026Current reportSEC
6-K · Report of a foreign issuerMar 10, 2026Current reportSEC
424B3 · ProspectusMar 5, 2026Offer documentSEC
6-K · Report of a foreign issuerMar 5, 2026Current reportSEC
6-K · Report of a foreign issuerMar 4, 2026Current reportSEC
6-K · Report of a foreign issuerMar 3, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 17, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 5, 2026Current reportSEC
6-K · Report of a foreign issuerJan 27, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
6-K · Report of a foreign issuerJan 16, 2026Current reportSEC
6-K · Report of a foreign issuerDec 29, 2025Current reportSEC
6-K · Report of a foreign issuerDec 23, 2025Current reportSEC
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
424B3 · ProspectusNov 21, 2025Offer documentSEC
6-K · Report of a foreign issuerNov 21, 2025Current reportSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 3, 2025Current reportSEC
6-K · Report of a foreign issuerSep 15, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveSep 12, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 12, 2025Other filingsSEC
POS AM · Amendment to an effective registrationSep 8, 2025Offer documentSEC
POS AM · Amendment to an effective registrationSep 8, 2025Offer documentSEC
POS AM · Amendment to an effective registrationSep 8, 2025Offer documentSEC
POS AM · Amendment to an effective registrationSep 8, 2025Offer documentSEC
POS AM · Amendment to an effective registrationAug 28, 2025Offer documentSEC
POS AM · Amendment to an effective registrationAug 28, 2025Offer documentSEC
6-K · Report of a foreign issuerAug 28, 2025Current reportSEC
6-K · Report of a foreign issuerJul 30, 2025Current reportSEC
424B4 · ProspectusJul 29, 2025Offer documentSEC
6-K · Report of a foreign issuerJul 29, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJul 29, 2025Other filingsSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
6-K · Report of a foreign issuerJul 28, 2025Current reportSEC
F-1/A · Registration statement, amendedJul 25, 2025Offer documentSEC
CORRESP · Letter to the SECJul 24, 2025Other filingsSEC
CORRESP · Letter to the SECJul 24, 2025Other filingsSEC
F-1 · Registration statementJul 23, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 22, 2025Other filingsSEC
CORRESP · Letter to the SECJul 17, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 15, 2025Other filingsSEC
DRS · Draft registration statementJul 9, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 30, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
UPLOAD · Letter from the SECJun 17, 2025Other filingsSEC
6-K · Report of a foreign issuerJun 16, 2025Current reportSEC
6-K · Report of a foreign issuerMay 16, 2025Current reportSEC
424B5 · ProspectusMay 9, 2025Offer documentSEC
6-K · Report of a foreign issuerMay 5, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 18, 2025Other filingsSEC
6-K · Report of a foreign issuerApr 17, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeApr 16, 2025Big-stake noticeSEC
424B5 · ProspectusApr 15, 2025Offer documentSEC
6-K · Report of a foreign issuerApr 15, 2025Current reportSEC
6-K · Report of a foreign issuerApr 14, 2025Current reportSEC
POS AM · Amendment to an effective registrationApr 14, 2025Offer documentSEC
6-K · Report of a foreign issuerApr 14, 2025Current reportSEC
6-K · Report of a foreign issuerApr 14, 2025Current reportSEC
20-F · Annual reportApr 14, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 24, 2025Current reportSEC
6-K · Report of a foreign issuerMar 20, 2025Current reportSEC
6-K · Report of a foreign issuerMar 19, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
6-K · Report of a foreign issuerMar 3, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 5, 2025Current reportSEC
6-K · Report of a foreign issuerJan 27, 2025Current reportSEC
6-K · Report of a foreign issuerDec 30, 2024Current reportSEC
6-K · Report of a foreign issuerDec 4, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 4, 2024Current reportSEC
6-K · Report of a foreign issuerOct 18, 2024Current reportSEC
6-K · Report of a foreign issuerOct 9, 2024Current reportSEC
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
6-K · Report of a foreign issuerSep 16, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveSep 9, 2024Other filingsSEC
424B3 · ProspectusSep 6, 2024Offer documentSEC
CORRESP · Letter to the SECSep 6, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 6, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 5, 2024Other filingsSEC
6-K · Report of a foreign issuerAug 30, 2024Current reportSEC
F-3 · Registration statementAug 30, 2024Offer documentSEC
POS AM · Amendment to an effective registrationAug 30, 2024Offer documentSEC
424B5 · ProspectusAug 30, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 29, 2024Current reportSEC
6-K · Report of a foreign issuerAug 12, 2024Current reportSEC
6-K · Report of a foreign issuerAug 9, 2024Current reportSEC
6-K · Report of a foreign issuerJul 29, 2024Current reportSEC
6-K · Report of a foreign issuerJul 11, 2024Current reportSEC
6-K · Report of a foreign issuerJul 3, 2024Current reportSEC
6-K · Report of a foreign issuerJul 1, 2024Current reportSEC
424B7 · ProspectusJun 28, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
6-K · Report of a foreign issuerJun 26, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 10, 2024Current reportSEC
6-K/A · Report of a foreign issuer, amendedJun 7, 2024Current reportSEC
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
6-K · Report of a foreign issuerMay 29, 2024Current reportSEC
6-K · Report of a foreign issuerMay 22, 2024Current reportSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
6-K · Report of a foreign issuerMay 9, 2024Current reportSEC
6-K · Report of a foreign issuerMay 6, 2024Current reportSEC
6-K · Report of a foreign issuerApr 25, 2024Current reportSEC
6-K · Report of a foreign issuerApr 15, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 10, 2024Other filingsSEC
S-8 · Registration statement for employee plansApr 5, 2024Offer documentSEC
POS AM · Amendment to an effective registrationApr 5, 2024Offer documentSEC
6-K · Report of a foreign issuerApr 3, 2024Current reportSEC
20-F · Annual reportMar 28, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 28, 2024Current reportSEC
6-K · Report of a foreign issuerMar 11, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 30, 2024Current reportSEC
6-K · Report of a foreign issuerJan 29, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJan 8, 2024Other filingsSEC
CORRESP · Letter to the SECJan 3, 2024Other filingsSEC
F-3/A · Registration statement, amendedDec 28, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 20, 2023Current reportSEC
6-K · Report of a foreign issuerDec 18, 2023Current reportSEC
F-3 · Registration statementDec 12, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 4, 2023Current reportSEC
6-K · Report of a foreign issuerNov 30, 2023Current reportSEC
424B3 · ProspectusNov 22, 2023Offer documentSEC
6-K · Report of a foreign issuerNov 22, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerOct 30, 2023Current reportSEC
6-K · Report of a foreign issuerOct 26, 2023Current reportSEC
6-K · Report of a foreign issuerOct 10, 2023Current reportSEC
6-K · Report of a foreign issuerSep 27, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveSep 13, 2023Other filingsSEC

This page holds 200 of 868 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Can-Fite BioPharma Ltd.’s releases · as of Mar 4, 2026

Common shares
6,063,093
Fully diluted
6,063,093

Fully diluted

LineShares
Common shares6,063,093

Share count over time

CountShares
Nov 22, 20266,063,093

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Sabby Management, LLC85,207US$187KSep 30, 2026
Citadel26,907US$59,195Sep 30, 2026
Rhumbline Advisers19,443US$42,770Sep 30, 2026
Jane Street13,324US$29,313Sep 30, 2026
GAMMA Investing LLC6,706US$14,753Sep 30, 2026
UBS2,739US$6,025Sep 30, 2026
Citigroup Inc2,175US$4,785Sep 30, 2026
BFC Planning, Inc.250US$550Sep 30, 2026
Fifth Third Bancorp150US$330Sep 30, 2026
Activest Wealth Management10US$22Sep 30, 2026
All 12 holders
HolderSharesValueAs of
Morgan Stanley1US$2Sep 30, 2026
TD1US$2Sep 30, 2026

Funds

HolderSharesValueAs of
Blackstone Alternative Multi-Strategy Fund50US$149Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Guy Regev
Other companies: Big Digital Energy, Inc. (Director · Nov 21, 2011 – Mar 18, 2012 · Past)
Chief Executive Officer · Since at least Mar 18, 2026
Yoseph Bornstein
Other companies: Microbot Medical Inc. (Director · Nov 28, 2016 – Nov 2, 2023 · Past)
Director · Since at least Mar 18, 2026
Abraham SartaniMember of the Board of Directors · Since at least Nov 6, 2026
Ilan TamirSince at least Nov 6, 2026
Motti FarbsteinCEO, CFO and COO · Since at least Mar 18, 2026
Pnina FishmanExecutive Chairperson, CSO · Since at least Mar 18, 2026
Sari FishmanVice President of Business Development · Since at least Mar 18, 2026
Yossi BornsteinCEO · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Can-Fite BioPharma Ltd.